GSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus even if it is taken only six times a year, instead of every month. ViiV said the ...

For ViiV Healthcare—the HIV-focused joint venture between GSK, Pfizer and Shionogi—the day represents a dual opportunity to both celebrate progress and plan next steps, according to Randevyn ...

GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophylaxis (PrEP) available in ...

GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced that the European Commission has authorised ...

GSK has today reported favourable findings from the Latitude phase III study of its long-acting injectable antiretroviral treatment (ART) for HIV. The study was conducted by Viiv Healthcare ...

British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus’s ...

A specialist HIV company, ViiV Healthcare is majority-owned by GSK while Shionogi and Pfizer are shareholders. "ViiV Healthcare and J&J’s adolescent HIV-1 combo gains EC authorisation" was ...

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...

(RTTNews) - GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced ... prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to disrupt the pre-exposure prophylaxis (PrEP) market with a twice-yearly ...

ViiV Healthcare is committed to ensuring timely public access for APRETUDE to help reduce the risk of sexually acquired HIV-1 infection and make progress towards global targets of ending HIV by ...